Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Leukemia, Myelomonocytic, Chronic 2Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 40fludarabine phosphate 38Peripheral Blood Stem Cell Transplantation 35Busulfan 32Tacrolimus 25Antilymphocyte Serum 25Filgrastim 24Radiotherapy 23Mycophenolic Acid 23Methotrexate 22Cyclosporine 21Etoposide 18Methylprednisolone 15Melphalan 15Whole-Body Irradiation 14Cytarabine 13Cord Blood Stem Cell Transplantation 12Psychiatric Rehabilitation 11Therapeutics 10Flow Cytometry 9sargramostim 7Sirolimus 7Polymerase Chain Reaction 6Alemtuzumab 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Carboplatin 5thymoglobulin 4ruxolitinib 4aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × axatilimab × Clear all
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡